The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.
Committee struggles to find a common treatment approach.
Christian Wieszner, CSL Behring UK’s new General Manager, talks about his role and his vision for the company’s UK operation going forward.
Rebrand launched to design, develop, and deliver specialist training, skills assessments and process consultancy to the healthcare and pharma industries.
Volume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.
PharmaLex has announced the launch of a new service line, Biopharma Excellence, and appointed a new Chief Medical Officer.
Foundational partnership enables access to novel datasets and innovation workflows through Eagle Genomics’ knowledge discovery platform.
OM Pharma, active in the prevention of recurrent respiratory and urinary tract infections, wins the 2021 Geneva Economy Award.
Treatment availability for rare disease patients under fire in Europe.
Sy Chyi Yeoh looks at some of the practical considerations faced by Chinese firms looking to expand overseas.
Funding will be used to further develop CC Bio’s microbiome editing technologies, which harness potent enzymes derived from bacterial viruses to seek out and destroy harmful and disease-causing bacteria.
Chairman of the Harvard China Fund, Dr. William C. Kirby, talks about the potential impact on multinational western pharma firms of disruption in China.
Liva Healthcare’s Philipp M. Schäfer talks about the company’s ambitions to drive a positive behavior change in type 2 diabetes.
Rory Mullen outlines Ireland’s importance to multinational pharma in the changing EU landscape.
Report claims an imbalance in influence of tech-transfer decisions.
Cliodhna McDonough-Stevens looks at what the COVID-19 pandemic might mean for the future of cell and gene therapy across Europe.
Wesam Badran looks at how the UK NHS can collaborate with pharma and med-tech partners to encourage digital innovation.
Summits, proposals outline advice on response to future pandemics.
How pharma firms assess their readiness for IDMP (Identification of Medicinal Products) is important for meeting compliance requirements and ensuring they are prepared for the digital product information management future, writes Adnan Jamil.
Andaman7 and Afrisda, Inc. sign partnership agreement to support digital health implementation in Africa.
Pandemic triggers urgency around supply chain initiatives.
The European Commission’s Genetically Modified Organism (GMO) legislation hurts Europe’s ability to attract clinical trials and delays patient access to transformative medicines, say European industry associations.
Becton, Dickinson and Company is to build a $200 million high-tech manufacturing facility in Zaragoza, Spain.
With a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.
The progress and stumbling blocks in building a formal EU system.
